P&G transfers Vicks medicated cough drop business in Japan to Taisho Pharmaceutical in deal announced May 14. Under agreement, Taisho obtains perpetual license rights to trademark, formula of Vicks Medicated Drops, as well as rights to all product sales; P&G will continue as contract manufacturer "for the foreseeable future," Taisho says. Firm also becomes exclusive sales agent of VicksVapoRub in Japan, although P&G will continue to manufacture the product. P&G says deal is part of its strategic decision to invest in larger markets; aside from Japan, Vicks Medicated Drops are only sold in India, Indonesia, Singapore and are not among top-selling Vicks offerings...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Japan gives world-first approval recommendations to two domestically originated drugs, for insomnia and glaucoma/ocular hypertension.
Japan looks set to press ahead with a reimbursement price cut for Eisai's Alzheimer's drug Leqembi following a cost-effectiveness review, despite differences with the company over methodology.
Country recommends eights new drugs for approval, including six for rare diseases, and also announces macroeconomic policy the pharma industry says would enable some reimbursement prices to be raised.
The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get your submissions in by this date. Sponsorship opportunities and tables for the event are also available.
Japan looks set to press ahead with a reimbursement price cut for Eisai's Alzheimer's drug Leqembi following a cost-effectiveness review, despite differences with the company over methodology.
Amid the wait for an action plan to apply AI tools to drug regulation at the national level in China, capital city Beijing has released its own vision of scenarios for the technology in the healthcare sector.
China has announced a raft of new measures to encourage innovative drug development across the product life cycle, including using insurance data to differentiate new therapies and applying commercial insurance to selected novel products.
